Emtricitabine/rilpivirine/tenofovir

Emtricitabine/rilpivirine/tenofovir is a fixed-dose combination of antiretroviral drugs used in the treatment and prevention of HIV/AIDS. This combination is marketed under the brand name Complera in the United States and Eviplera in the European Union.

Composition

The combination consists of three active ingredients:

• Emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI)
• Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI)
• Tenofovir disoproxil, a nucleotide reverse transcriptase inhibitor (NtRTI)

Mechanism of Action

Each of the three drugs in this combination works by inhibiting the action of reverse transcriptase, an enzyme that HIV uses to replicate its genetic material. By blocking this enzyme, the drugs prevent the virus from multiplying, thereby reducing the amount of virus in the body.

Usage

Emtricitabine/rilpivirine/tenofovir is used as part of antiretroviral therapy (ART) for people with HIV. It is also used as pre-exposure prophylaxis (PrEP) to prevent HIV infection in people at high risk.

Side Effects

Common side effects include headache, dizziness, and nausea. Serious side effects may include liver problems, kidney problems, and a build-up of lactic acid in the blood.

Interactions

Emtricitabine/rilpivirine/tenofovir can interact with other drugs, including other antiretrovirals, antacids, and certain antibiotics and antifungals. It is important to tell your healthcare provider about all the medications you are taking.

See Also

• Antiretroviral therapy
• HIV/AIDS
• Pre-exposure prophylaxis